Compare Cassava Sciences Inc (FLNA) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Ross Stores, Inc. — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Ross Stores, Inc. trades at $232.82 (market cap $72.47B). The key difference: Ross Stores, Inc. is far larger — about 1363.8× Cassava Sciences Inc's market cap, and Ross Stores, Inc. pays a 0.79% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | ROST | |
|---|---|---|
Market Cap | $53.14M | $72.47B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $240.13 |
52-Week Low | $1.09 | $129.10 |
Enterprise Value | -$33.43M | $73.07B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Ross Stores (ROST) trades at $232.89, up 5.43% today, reflecting strong momentum after three consecutive quarterly earnings beats. The stock shows bullish technical signals with support at $223 and resistance at $233. Fundamentally, ROST demonstrates robust profitability with a 38.98% ROE and 9.74% net margin, supported by revenue growth to $21.13B in 2025. Recent news highlights include a Zacks Strong Buy upgrade on June 15, 2026, and inclusion in high-ROE stock lists amid market volatility.
The outlook for ROST remains positive with a consensus price target of $259, suggesting 11% upside. Key opportunities include sustained earnings growth and expanding store footprint, while risks involve consumer spending sensitivity and competitive pressures. Institutional sentiment is bullish with 64% buy ratings, though elevated P/E of 31.55 warrants valuation monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
